Clinical Trial Update: Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) [Phase 3]

View source ↗

Summary

This entry documents the completed Phase III SWITCH-II trial, which compared sequences of sorafenib followed by pazopanib versus pazopanib followed by sorafenib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Votrient (Pazopanib)

Snippet

Sponsor: Technical University of Munich | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED